Ian M Catlett
4PUBLICATIONS
16CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Sep 16, 2024
Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial.Ian M Catlett, Lu Gao, Yanhua Hu
|Nov 03, 2022
First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2.Ian M Catlett, Urvi Aras, Lars Hansen
|Mar 22, 2020
Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.Ian M Catlett, Miroslawa Nowak, Sudeep Kundu
|Jul 26, 2019
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain.James R Burke, Lihong Cheng, Kathleen M Gillooly
Pageof 1
Frequent Collaborators
1 joint publications
James R Burke
1 joint publications
Adriana Zupa-Fernandez
1 joint publications
Elizabeth M Heimrich
1 joint publications
Kim W McIntyre
1 joint publications
Mark D Cunningham
1 joint publications
Julie A Carman
1 joint publications
Dana Banas
1 joint publications
Jenny H Xie
1 joint publications
Ryan M Moslin
1 joint publications
Stephen T Wrobleski
